DrugPatentWatch Database Preview

LAZANDA Drug Profile

« Back to Dashboard

When do Lazanda patents expire, and what generic alternatives are available?

Lazanda is a drug marketed by Btcp Pharma and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-two patent family members in thirty countries.

The generic ingredient in LAZANDA is fentanyl citrate. There are thirty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.

US ANDA Litigation and Generic Entry Outlook for Lazanda

A generic version of LAZANDA was approved as fentanyl citrate by HOSPIRA on January 17^th, 2020.

Summary for LAZANDA

International Patents:	62
US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	26
Clinical Trials:	5
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for LAZANDA
DailyMed Link:	LAZANDA at DailyMed

See drug prices for LAZANDA

Recent Clinical Trials for LAZANDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Diego	Phase 2
Depomed	Phase 4
Defense and Veterans Center for Integrative Pain Management	Phase 4

See all LAZANDA clinical trials

Pharmacology for LAZANDA

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

Synonyms for LAZANDA

1-(2-Phenylethyl)-4-(N-propananilido)piperidine

1-Phenethyl-4-(N-phenylpropionamido)piperidine

1-Phenethyl-4-N-propionylanilinopiperidine

437-38-7

5-22-08-00049 (Beilstein Handbook Reference)

80832-90-2

9235-EP2275420A1

9235-EP2277861A1

9235-EP2277875A2

9235-EP2280008A2

9235-EP2298764A1

9235-EP2298765A1

9235-EP2298768A1

9235-EP2305652A2

9235-EP2305654A1

9235-EP2308509A1

9235-EP2308872A1

9235-EP2314585A1

9235-EP2314590A1

9235-EP2316829A1

990-73-8 (citrate)

AC1L1FQ2

ACN-S001735

API0002693

BDBM50008984

BIDD:GT0555

BRN 0494484

CAS-437-38-7

CF0052

CHEBI:119915

CHEMBL596

CS-7211

CTK8G2863

D00320

DB00813

DSSTox_CID_3049

DSSTox_GSID_23049

DSSTox_RID_76851

DTXSID9023049

Duragesic

Duragesic (TN)

Duragesic-100

Duragesic-12

Duragesic-25

Duragesic-50

Duragesic-75

Durogesic

Durotep MT

effentora

EINECS 207-113-6

Epitope ID:153507

Fentanest

Fentanil

Fentanil [DCIT]

Fentanila

Fentanila [INN-Spanish]

Fentanilo

fentanyl

Fentanyl (JAN/USAN/INN)

Fentanyl [INN:BAN]

Fentanyl [USAN:USP:INN:BAN]

Fentanyl 0.1 mg/ml in Methanol

Fentanyl 1.0 mg/ml in Methanol

Fentanyl buccal

Fentanyl CII

Fentanyl solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Fentanyl solution, 100 mug/mL in methanol, ampule of 1 mL, certified reference material

Fentanyl Transdermal System

Fentanyl-100

Fentanyl-12

Fentanyl-25

Fentanyl-50

Fentanyl-75

FENTANYL-HCl

Fentanylum

Fentanylum [INN-Latin]

Fentora

FT-0668508

GTPL1626

HSDB 3329

HY-U00158

IONSYS

JNS020QD

L001275

LS-124439

Matrifen

N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide

N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide

N-(1-Phenethyl-4-piperidyl)propionanilide

N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide

N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide(Fentanyl)

N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide

N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide

N-(1-Phenylethyl-4-piperidinyl)propionanilide

N-Phenethyl-4-(N-propionylanilino)piperidine

N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide

N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide #

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide

NCGC00168252-01

Oprea1_152073

Oprea1_207148

PDSP1_000860

PDSP2_000846

PecFent

Phentanyl

PJMPHNIQZUBGLI-UHFFFAOYSA-N

Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-

Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)

Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-

Propionanilide, N-(1-phenethyl-4-piperidyl)-

R 4263

R4263

SCHEMBL8804

Sentonil

Sublimase

Sublimaze

Subsys

Subsys (TN)

Tox21_112611

UF599785JZ

UNII-UF599785JZ

ZINC2522669

US Patents and Regulatory Information for LAZANDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-001	Jun 30, 2011		RX	Yes	No
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-003	Dec 21, 2015		DISCN	Yes	No			Y
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-001	Jun 30, 2011		RX	Yes	No			Y

Expired US Patents for LAZANDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-001	Jun 30, 2011
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-002	Jun 30, 2011

International Patents for LAZANDA

Country	Patent Number	Estimated Expiration
Slovenia	2670674
European Patent Office	1635783
Hong Kong	1088555

Supplementary Protection Certificates for LAZANDA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0836511	CA 2006 00019	Denmark		PRODUCT NAME: FENTANYL HYDROCHLORID
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
1635783	CA 2014 00016	Denmark		PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831